---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-033240"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:24:33.497290+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment

## Summary
- Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.
- Pro forma adjusted net loss improved to $6.5M ($0.16 loss per share) from $5.4M ($0.14 loss) in Feb 2023.
- Pro forma net sales for continuing ops were $66.0M, down 6.9% as reported but up 8.0% constant currency vs prior year.
- Med Tech segment pro forma sales grew 13.0% to $25.7M; Med Device segment pro forma sales down 14.7% as reported.
- Pro forma adjusted EBITDA loss narrowed to $3.6M from $1.5M in the year-ago quarter.

## SEC filing metadata
- accession: 0001140361-24-033240
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036124033240/0001140361-24-033240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036124033240/ef20032494_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-033240
- JSON: https://secwatch.observer/filing/0001140361-24-033240.json
- Plain text: https://secwatch.observer/filing/0001140361-24-033240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.